Yahoo Web Search

Search results

1. People also ask

   Are the free test kits from the government expired?
   Where to get free COVID testing near me?
   Is the pandemic over?
   How long to quarantine after COVID exposure?
   Who can get the free in-home test kits?

2. www.nejm.org › doi › fullNirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients ...

   www.nejm.org › doi › full

   Apr 3, 2024 · Nirmatrelvir is an orally administered antiviral agent that inhibits the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro), which is critical for viral...

3. www.nejm.org › coronavirusCoronavirus (Covid-19) | NEJM - The New England Journal of ...

   www.nejm.org › coronavirus

   Apr 3, 2024 · Explore a collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary.

4. www.nejm.org › doi › fullOral Simnotrelvir for Adult Patients with Mild-to-Moderate ...

   www.nejm.org › doi › full

   Apr 24, 2024 · To the Editor: Cao et al. (Jan. 18 issue) 1 evaluated changes in log 10 copies of SARS-CoV-2 RNA per milliliter in adults with mild-to-moderate Covid-19 receiving simnotrelvir or placebo.

5. www.nih.gov › news-events › news-releasesPeer-reviewed report on Moderna COVID-19 vaccine publishes

   www.nih.gov › news-events › news-releases

   • Cached

   • What
   • Article
   • Who
   • Contact

   The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine.The vaccine also demonstrated efficacy in preventing severe COVID-19. Investigators identified no safety co...

   See full list on nih.gov

   LR Baden, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2035389.

   See full list on nih.gov

   NIAID Director Anthony S. Fauci, M.D. is available to comment on this study. John R. Mascola, M.D., director of NIAID’s Vaccine Research Center, is also available to comment.

   See full list on nih.gov

   To schedule interviews, please contact the NIAID News & Science Writing Branch, (301) 402-1663, niaidnews@niaid.nih.gov(link sends e-mail). NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing...

   See full list on nih.gov

6. pubmed.ncbi.nlm.nih.gov › 35172054Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with ...

   pubmed.ncbi.nlm.nih.gov › 35172054

   Apr 14, 2022 · Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns. (Supported by Pfizer; ClinicalTrials.gov number, NCT04960202.).

7. covid19rx.nejm.org › landing › indexCovid-19 Rx: A Clinical Reasoning Simulator

   covid19rx.nejm.org › landing › index

   • Cached

   Covid-19 Rx: Treatment Simulations. You are a health care provider in a developed country. Several patients await your care. These patients are suspected of having Covid-19 and have been...

8. catalyst.nejm.org › covid-19Covid-19 - The New England Journal of Medicine

   catalyst.nejm.org › covid-19

   Coronavirus (Covid-19): Stay current with the latest clinical research and resources from our sister publications, the New England Journal of Medicine coronavirus page and NEJM...